SIEMENS

Dimension Vista LOCI TPSA/FPSA Assay Specifications

www.siemens.com/diagnostics

The Siemens Healthcare Diagnostics Dimension Vista® LOCI® TPSA and FPSA assays are homogeneous, sandwich chemiluminescent immunoassays based on LOCI technology.

Outstanding Assay Performance

- Free PSA and complexed PSA recognized on an equimolar basis
- Excellent precision to ensure accurate monitoring—TPSA: 2.31%-5.18% CV; FPSA: 2.32%-3.78% CV
- Rapid assay kinetics (10 minutes)

Dimension Vista System— Intelligence at Work

- Ultra-integration—Four technologies in one smart workstation: photometry, nephelometry, LOCI advanced chemiluminescence, and V-LYTE® integrated multisensor technology
- LOCI advanced chemiluminescence— The only homogeneous chemiluminescent technology
- Onboard automation—Increased efficiency, simplicity, and convenience for your laboratory



Clinical Utility				
LOCI TPSA	LOCI FPSA			
Aid for the detection of prostate cancer when used in conjunction with digital rectal exam (DRE) in men 50 years or older	Percent FPSA is used as an aid in distinguishing prostate cancer from benign prostate conditions when PSA is in the "gray zone" range of 4 to 10 ng/mL			
Aid in the management (monitoring) of prostate cancer patients	Percent FPSA result may be used in two ways: (1) to provide an individual patient risk assessment of prostate cancer or (2) use a single cutoff to indicate the need for additional follow-up			
More effective when combined with a DRE in detecting prostate cancer than DRE alone	A cutoff of 19% results in the detection of 90.2% of prostate cancers and avoids unnecessary biopsy in 18.1% of men without prostate cancer			

Dimension Vista LOCI TPSA/FPSA Assay Specifications

LOCI TPSA as an Aid in the Detection of Prostate Cancer with DRE

The positive predictive value (PPV) was estimated as the probability of having a positive biopsy given a positive result for DRE, PSA, and PSA with DRE. The results are as follows:

Method	PPV%	95% Confidence Interval
DRE+ only	42.6	38.1-47.2
PSA ≥4.0 only	42.4	39.6-45.3
PSA ≥4.0 or DRE+	39.3	36.7-42.0
PSA ≥4.0 and DRE+	57.2	51.3-62.9
PSA ≥4.0 and DRE-	37.6	34.4-40.8

PSA concentrations, regardless of value, should not be interpreted as definitive evidence for the presence or absence of prostate cancer.

Prostate biopsy is required for the diagnosis of cancer.

Percentage (%) of Patients with Diagnosis of Prostate Cancer on Biopsy: Men with Non-Suspicious DRE Results

Total PSA Range 4.0 to 10.0 ng/mL	% Free PSA	All Ages
	≤10%	53.5%
	11–19%	28.4%
	≥20%	22.6%
Prostate Cancer Prevalence (%)		35.0%

Performance Summary

	Sample Type	Sample Volume	Assay Range	Limit of Detection	Cutoff	Calibration Interval	Onboard Stability
Dimension Vista LOCI TPSA	Serum/Plasma	3 µL	0.010-100 ng/mL	0.008 ng/mL	4.0 ng/mL	30 days	30 days
Dimension Vista LOCI FPSA	Serum/Plasma	3 μL	0.015-20 ng/mL	0.005 ng/mL	19%	30 days	30 days

Ordering Information			
Catalog No.	Description	Contents	
K6451	PSA Flex® Reagent Cartridge	120 tests	
K6452	FPSA Flex® Reagent Cartridge	80 tests	
KC602	PSA Calibrator	2 x 6 levels	

Siemens Healthcare Diagnostics, a global leader in clinical diagnostics, provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the vital information required to accurately diagnose, treat, and monitor patients. Our innovative portfolio of performance-driven solutions and personalized customer care combine to streamline workflow, enhance operational efficiency, and support improved patient outcomes.

Dimension Vista, Flex, LOCI, V-LYTE, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc. All other trademarks and brands are the property of their respective owners. Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.

Global Siemens Headquarters

Siemens AG Wittelsbacherplatz 2 80333 Muenchen Germany

Global Siemens Healthcare Headquarters

Siemens AG Healthcare Sector Henkestrasse 127 91052 Erlangen, Germany Phone: +49 9131 84 - 0 www.siemens.com/healthcare

Global Division

Siemens Healthcare Diagnostics Inc. 511 Benedict Avenue Tarrytown, NY 10591-5005 USA www.siemens.com/diagnostics

Order No. A91DX-CAI-110283-GC1-4A00 01-2012 | All rights reserved © 2012 Siemens Healthcare Diagnostics Inc.